EUCTR2008-000422-39-NL进行中（未招募）1 期
A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer
Merck Shap @ Dohme0 个研究点目标入组 156 人开始时间: 2008年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patient has histologically confirmed adenocarcinomas of the prostate.
- •2. Archival pathological material is available for submission to central laboratory.
- •3. Patient has evidence of metastatic disease at protocol entry or at the time of prior hormonal manipulation, determined radiographically by the presence of at least 2 bone scan lesions consistent with metastases or abdominal/pelvic lymph nodes > 2 cm on longest axial measurement. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or magnetic resonance imaging (MRI).
- •4. Patient has evidence of disease progression despite castrate levels of testosterone (< 50 ng/dl) following orchiectomy or during therapy with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist (with or without an anti-androgen). Evidence of disease progression must include one of the following:
- •a) Levels of PSA are defined as increasing when at least three consecutive measurements, obtained at least one week apart, show increases. (The minimum starting PSA level for trial entry is 10 ng/mL.)
- •b) Progressive lymph node disease is defined per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The longest diameter of any node must measure at least 2 cm on spiral computed tomography (CT) to qualify as a target lesion.
- •c) Worsening bone scan is defined as an increase of 2 or more lesions from a previous bone scan. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or MRI.
- •5. Patient has a PSA > 10 ng/ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient has received bicalutamide, flutamide, or nilutamide within the past 12 months.
- •2. Patient has received prior chemotherapy for metastatic prostate cancer.
- •3. Patient has previously received rapamycin or rapamycin analogs, including deforolimus, temsirolimus, or everolimus.
- •4. Patient is receiving corticosteroids administered at doses greater than those used for normal replacement therapy. .
- •5. Patient is receiving an opioid or narcotic analgesic prescribed for pain due to prostate cancer.
- •6. In the opinion of the investigator, the patient has pain related to metastatic prostate cancer that warrants the initiation of chemotherapy.
研究者
相似试验
进行中（未招募）
不适用
A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate CancerMedDRA version: 13.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic prostate cancerEUCTR2008-000422-39-GBMerck Sharp & Dohme Corp.180
进行中（未招募）
不适用
A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate CancerMedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticMetastatic prostate cancerEUCTR2008-000422-39-FIMSD Finland Oy156
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-BECB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-LTCB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007systemic lupus erythematosusEUCTR2007-002566-35-GBCB Inc210